trending Market Intelligence /marketintelligence/en/news-insights/trending/o2dxMH13f5IJSh-Uy91UVg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Lilly completes separation of Elanco Animal Health

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Lilly completes separation of Elanco Animal Health

Eli Lilly and Co. completed its separation from Elanco Animal Health Inc. after completing an exchange offer to divest its 80.2% stake in the animal health business.

Indianapolis-based Eli Lilly spun off the animal health unit in 2018 through a $1.7 billion NYSE IPO. The drugmaker is separating from the business to focus on its human pharmaceutical business.

Lilly is divesting its ownership in Elanco in the exchange offer, with shareholders receiving 4.5121 Elanco common shares for each Eli Lilly common share they own.

The company plans to update GAAP and non-GAAP financial guidance at its first-quarter earnings announcement on April 30 to account for the separation.

Goldman Sachs & Co. LLC, J.P. Morgan and Morgan Stanley were the dealer managers for the exchange offer.

Elanco on Feb. 6 reported non-GAAP net income of $105.4 million for the fourth quarter of 2018, an increase of 148% from $42.5 million in the prior-year period.